Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)
Christian T. Ruff(Brigham and Women's Hospital), Eugene Braunwald(Mass General Brigham), Sharon Crugnale(Brigham and Women's Hospital), Robert P. Giugliano(Thrombolysis in Myocardial Infarction Study Group), James Hanyok(Daiichi Sankyo (United States)), Dan Salazar(Daiichi Sankyo (United States)), Michele Mercuri(Inserm), Tomás S. Bocanegra(Daiichi Sankyo (United States)), Carolyn H. McCabe(Brigham and Women's Hospital), Indravadan Patel(Daiichi Sankyo (United States)), Minggao Shi(Daiichi Sankyo (United States)), Elliott M. Antman(Brigham and Women's Hospital)
Cited by 482
Related Papers
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
|New England Journal of Medicine|2015|2k